MET and neoplasm: MEG3 directly targets the proto-oncogene c-MET (hepatocyte growth factor receptor) to block cell proliferation and delay cell cycle progression, and it also displays an anti-tumor effect through manipulating the p38/ERK/Akt and Wnt/β-catenin pathway in a MEG3/miR183/BRI3 dependent manner (66).